GlassScriptPhysician profile
Leroy Wayne Keiser
NPI 1417047283
$484,096.28
in general payments reported to CMS, 2019-2025
33 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $62K · 2021: $55K · 2022: $104K · 2023: $60K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $20K · Consulting Fee: $7,920 · Food and Beverage: $1,992 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,522.75 |
| Travel and Lodging | $20,387.46 |
| Consulting Fee | $7,920.00 |
| Food and Beverage | $1,992.41 |
| Education | $112.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291,430.45 | 2019-2025 | Lumakras, Imdelltra (Amg757), Xgeva |
| Exelixis INC. | $73,448.63 | 2019-2023 | Cabometyx |
| Incyte Corporation | $67,345.67 | 2019-2023 | Jakafi |
| Teva Pharmaceuticals USA, INC. | $15,733.87 | 2019 | |
| Taiho Oncology, INC. | $11,184.59 | 2019-2021 | |
| Pfizer INC. | $10,872.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,733.56 | 2019-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $3,821.36 | 2019 | |
| Clovis Oncology, INC. | $2,100.00 | 2020 | |
| Glaxosmithkline, LLC. | $1,734.66 | 2021-2022 | |
| Janssen Biotech, INC. | $246.66 | 2019-2025 | Akeega, Balversa, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $209.49 | 2021-2022 | |
| Lilly USA, LLC | $195.78 | 2019-2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $133.62 | 2021-2025 | Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $111.03 | 2019-2025 | Iclusig |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $108.02 | 2019-2022 | |
| Eisai INC. | $81.59 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $75.89 | 2019-2022 | |
| Genentech USA, INC. | $60.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $54.51 | 2019 | |
| Adc Therapeutics America, INC. | $51.51 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $49.56 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $47.01 | 2019-2021 | |
| Gilead Sciences, INC. | $45.71 | 2021-2025 | Trodelvy |
| Kite Pharma, INC. | $44.45 | 2021-2022 | |
| Astellas Pharma US INC | $30.78 | 2021-2022 | |
| Abbvie INC. | $28.04 | 2025 | |
| Daiichi Sankyo INC. | $27.09 | 2025 | Enhertu |
| Foundation Medicine, INC. | $20.22 | 2019 | |
| Shire North American Group INC | $20.00 | 2019 | |
| Emd Serono, INC. | $18.59 | 2019 | |
| Ge Healthcare | $16.76 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.